Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -42

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

AI-generated analysis

📉 Phase 3 trial results failed to show statistically significant improvement in progression-free survival for high-dose fianlimab combination compared to pembrolizumab monotherapy.

⏱️ A numeric increase of 5.1 months in median progression-free survival was observed for the high-dose fianlimab group versus standard-of-care pembrolizumab.

💊 No new safety signals were identified during the evaluation of the fianlimab and cemiplimab combination therapy.

👥 The trial enrolled 1,546 patients aged 12 years or older with unresectable locally advanced or metastatic melanoma who had not received prior systemic treatment.

💉 Treatment arms included high-dose (1600 mg fianlimab/350 mg cemiplimab), low-dose (400 mg fianlimab/350 mg cemiplimab), and placebo-pembrolizumab or placebo-cemiplimab combinations.

⏳ Detailed results will be presented at an upcoming medical meeting, with full data analysis still ongoing.

🔬 A separate Phase 3 head-to-head trial evaluating high-dose fianlimab combination against Opdualag® (nivolumab and relatlimab-rmbw) is currently in progress.

⚠️ Regeneron noted that the potential uses of this combination remain investigational, with safety and efficacy not yet evaluated by any regulatory authority.

🏢 Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, and is led by physician-scientists focusing on translating science into medicine.

🧬 The company utilizes proprietary technologies like VelociSuite® to develop fully human antibodies and new classes of bispecific antibodies.

🚀 Regeneron’s pipeline covers serious diseases including cancer, neurological disorders, eye diseases, and cardiovascular conditions.

📢 Company representatives provided updates via a press release dated May 15, 2026, distributed through GLOBE NEWSWIRE.

⚠️ Forward-looking statements regarding future events and product approvals are subject to various risks and uncertainties.

🌐 Investors and the public can follow further developments on Regeneron’s official website and social media channels including LinkedIn, Instagram, Facebook, and X.

Bullish Signals
  • A numeric improvement of 5.1 months in median progression-free survival (PFS) was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy.
  • The trial evaluated two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab, exploring multiple therapeutic approaches within the study design.
  • The Phase 3 head-to-head trial evaluating high-dose fianlimab versus Opdualag ® is ongoing, indicating continued development and potential future data for this candidate.
  • No new safety signals were identified with the fianlimab combination during the study, supporting the favorable safety profile observed thus far.
  • Regeneron is developing multiple dose levels (high-dose and low-dose) of fianlimab, providing flexibility in combination therapies to optimize efficacy.
Risk Factors
  • The Phase 3 trial for Fianlimab did not reach statistical significance for its primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab monotherapy.
  • Although a numeric improvement of 5.1 months in median PFS was observed with the high-dose fianlimab combination, this fell short of meeting the statistically significant threshold required for approval.
  • The combination therapy's efficacy has not yet been evaluated by any regulatory authority, leaving future approval uncertain despite the observed numeric benefits.
  • No new safety signals were identified, but the failure to meet the primary endpoint means the drug faces significant headwinds compared to existing standard-of-care treatments like pembrolizumab.
  • A separate Phase 3 head-to-head trial comparing high-dose fianlimab against Opdualag (nivolumab and relatlimab-rmbw) is ongoing, introducing competitive risk if Opdualag demonstrates superior results.
Full Analysis
Regeneron Pharmaceuticals announced today, May 15, 2026, results from a Phase 3 clinical trial evaluating fianlimab, a LAG-3 inhibitor, in combination with cemiplimab, a PD-1 inhibitor, as first-line treatment for unresectable locally advanced or metastatic melanoma. The study involved 1,546 patients aged 12 years and older who had not previously received systemic treatment for advanced disease. Participants were randomized to receive either a high-dose combination of fianlimab and cemiplimab (1,600 mg and 350 mg, respectively), a low-dose combination (400 mg and 350 mg), or pembrolizumab monotherapy as the control group. The high-dose combination demonstrated a median progression-free survival improvement of 5.1 months compared to pembrolizumab, though this numeric difference did not reach statistical significance for the primary endpoint of improved progression-free survival versus the single-agent therapy, with a p-value of 0.0627 when comparing the high-dose combination to pembrolizumab and a p-value of 0.4661 when comparing it to cemiplimab monotherapy using the low-dose cohort as a subset comparison. The company noted no new safety signals were identified with the fianlimab combination during the trial period. Regeneron emphasized that while the high-dose fianlimab and cemiplimab combination did not meet the primary efficacy endpoint against pembrolizumab monotherapy, detailed results will be presented at an upcoming medical meeting for further analysis. The company has also indicated that a Phase 3 head-to-head trial is currently ongoing to evaluate the high-dose fianlimab combination directly against Opdualag, a combination therapy consisting of nivolumab and relatlimab-rmbw, in patients with first-line unresectable or metastatic melanoma. These investigational uses have not yet been evaluated by regulatory authorities, and approval status remains pending. Regeneron highlighted its broader pipeline includes proprietary technologies like VelociSuite for antibody development and genetic medicine platforms via the Regeneron Genetics Center, focusing on treating serious diseases across various therapeutic areas including cancer, ophthalmology, immunology, and rare conditions.